Durability of Integrase STrand Inhibitor

• Published in: PloS one 2021-10, Vol.16 (10), p.e0258533
• Main Authors: Focà, Emanuele, Calcagno, Andrea, Calza, Stefano, Renzetti, Stefano, Chiesa, Annacarla, Siano, Matteo, De Socio, Giuseppe, Piconi, Stefania, Orofino, Giancarlo, Madeddu, Giordano, Cattelan, Anna Maria, Nozza, Silvia, Ferrara, Micol, Milic, Jovana, Celesia, Benedetto Maurizio, Castelli, Francesco, Guaraldi, Giovanni
• Format: Article
• Language: English
• Subjects: Aged patients; Care and treatment; HIV infection
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0258533

To investigate the durability of the first integrase inhibitor-based regimen in a HIV geriatric multicentric prospective cohort and to explore the reasons of regimen discontinuation. This is an analysis conducted on the Geriatric Patients Living with HIV/AIDS (GEPPO) cohort, an Italian prospective observational multicentre cohort of people living with HIV with 65 years of age or more. The analysis was performed using R (version 4.0.2). The tests performed were two sided assuming a 5% significance level (Kruskal-Wallis test, Chi-squared test, log-rank test and a Cox Proportional Hazard model). The proportion of participants discontinuing the three regimens was displayed using cumulative curves. Among 1531 patients enrolled between 2017 and 2019 in the GEPPO cohort, we included 822 participants in this analysis. At baseline, median age was 69.8, the immunovirological profile good, multimorbidity was present in 42.3% of participants, while 27.4% were on polypharmacy. Overall, 483, 243 and 96 participants received DTG, RAL and EVG/c respectively as first InSTI. At the end of the follow up 6.4%, 21.1% and 22.9% participants discontinued DTG, RAL and EVG/c respectively. Using a log-rank test, EVG showed a significantly lower durability than DTG (p